33. Padilla J, Hamilton SA, Lundgren EA, McKenzie JM, Mickleborough TD. Exercise training in normobaric hypoxia: is carbonic anhydrase III the best marker of hypoxia? *J Appl Physiol.* 2007;103:730–732.
34. Grigsby PW, Malyapa RS, Higashikubo R, et al. Comparison of molecular markers of hypoxia and imaging with ^{60}Cu-ATSM in cancer of the uterine cervix. *Mol Imaging Biol.* 2007;9:278–283.
35. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent ^{64}Cu(II)-diacetyl-bis(N^4-methylthiosemicarbazone). *J Nucl Med.* 2006;47:989–998.
36. Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of $^{60/61/62/64}$Cu-ATSM: a hypoxia imaging agent for PET. *Eur J Nucl Med Mol Imaging.* 2005; 32:764–770.
37. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. *J Biol Inorg Chem.* 2002;7:249–259.
38. Langberg H, Bulow J, Kjaer M. Standardized intermittent static exercise increases peritendinous blood flow in human leg. *Clin Physiol.* 1999;19:89–93.
39. Matsumoto K, Szajek L, Krishna MC, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [^{64}Cu]Cu-ATSM or [^{18}F]fluoromisonidazole positron emission tomography. *Int J Oncol.* 2007;30: 873–881.
40. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of ^{64}Cu-ATSM in vitro and in vivo in a hypoxic tumor model. *J Nucl Med.* 1999;40:177–183.

Erratum

In the article "PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody Against the Prostate-Specific Membrane Antigen," by Elsässer-Beile et al. (*J Nucl Med.* 2009;50:606–611), the image used for Figure 1 was incorrect. The corrected Figure 1 appears below. The authors regret the error.



FIGURE 1. Binding of 3/A12 mAb and DOTA-3/A12 mAb, with and without serum preincubation, to PSMA-positive C4-2 cells. Cells were treated with increasing concentrations (0.15–800 nM) of first-step anti-PSMA mAb followed by incubation with saturating amount of second-step phycoerythrin-labeled goat antimouse IgG followed by cytofluorometric analysis. MFI = mean fluorescence intensity.